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Abstract
Background: Evidence for the role of the gut microbiome in the pathogenesis of non-alcoholic fatty liver disease
(NAFLD) is emerging. Strategies to manipulate the gut microbiota towards a healthier community structure are
actively being investigated. Based on their ability to favorably modulate the gut microbiota, prebiotics may provide
an inexpensive yet effective dietary treatment for NAFLD. Additionally, prebiotics have established benefits for
glucose control and potentially weight control, both advantageous in managing fatty liver disease. Our objective
is to evaluate the effects of prebiotic supplementation, adjunct to those achieved with diet-induced weight loss,
on heptic injury and liver fat, the gut microbiota, inflammation, glucose tolerance, and satiety in patients with NAFLD.
Methods/design: In a double blind, placebo controlled, parallel group study, adults (BMI ≥25) with confirmed
NAFLD will be randomized to either a 16 g/d prebiotic supplemented group or isocaloric placebo group for
24 weeks (n = 30/group). All participants will receive individualized dietary counseling sessions with a registered dietitian
to achieve 10 % weight loss. Primary outcome measures include change in hepatic injury (fibrosis and inflammation) and
liver fat. Secondary outcomes include change in body composition, appetite and dietary adherence, glycemic
and insulinemic responses and inflammatory cytokines. Mechanisms related to prebiotic-induced changes in
gut microbiota (shot-gun sequencing) and their metabolic by-products (volatile organic compounds) and de
novo lipogenesis (using deuterium incorporation) will also be investigated.
Discussion: There are currently no medications or surgical procedures approved for the treatment of NAFLD
and weight loss via lifestyle modification remains the cornerstone of current care recommendations. Given
that prebiotics target multiple metabolic impairments associated with NAFLD, investigating their ability to modulate
the gut microbiota and hepatic health in patients with NAFLD is warranted.
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Background
Non-alcoholic fatty liver disease (NAFLD) is now the
most common cause of chronic liver disease worldwide
[1]. NAFLD can progress from simple steatosis to non-
alcoholic steatohepatitis (NASH) and finally to cirrhosis
and its complications (e.g. hepatocellular carcinoma) [1].
Currently the prevalence of NAFLD is 20-30 % of the
general population in affluent countries [2–4]. Since
NAFLD is a pathological condition closely associated
with obesity and insulin resistance [5], it could be ex-
pected that rates will continue to rise in conjunction
with the growing severity of obesity [6].
NAFLD Pathogenesis
In 1998, Day and James [7] proposed a ‘two hit’ hypoth-
esis to describe the pathogenesis of NAFLD whereby in-
sulin resistance [8] contributes to steatosis (first hit),
which sensitizes the liver to oxidative stress (second hit)
leading to inflammation, fibrosis and necrosis. Additional
theories, such as the multiple-hit hypothesis, suggest fac-
tors including adipokines and mitochondrial dysfunction
may also contribute to NAFLD [9]. Unrestrained free fatty
acid flux from adipose tissue has been implicated as a pri-
mary contributor to steatosis [10, 11], however recent
work has indicated that de novo lipogenesis is significantly
elevated in NAFLD patients and contributes to both
plasma and hepatic fatty acid levels [12–14].
The prevalence of NAFLD is estimated to be as high
as 75 % in individuals with obesity, 93 % in individuals
with morbid obesity, and 47-87 % in people with type 2
diabetes [1]. From a clinical perspective, it is not the
simple steatosis that is of concern, but rather the pro-
gression to NASH and fibrosis that carries risk for mor-
bidity and mortality [15]. Among individuals with
NAFLD, 10 % will progress to NASH, and a third of
those patients with early-stage NASH will progress to
cirrhosis within 5–10 years, putting tremendous strain
on liver transplant registries [16]. In the United States,
there was an 8-fold increase in liver transplants attrib-
uted to NAFLD between 2001 and 2009 [17]. Aside from
hepatic damage, steatosis may accelerate the progression
of dyslipidemia, insulin resistance, and atherosclerosis
[18], as well as increase the risk for cardiovascular [19]
and kidney disease [20]. Given the increased pressure on
already over-burdened health care systems, this patient
population represents a group in need of effective treat-
ments. As yet, there is a lack of approved treatments for
patients with NAFLD, particularly with fibrosis, and
therefore investigation of promising targets, including
dietary interventions, are critically needed.
NAFLD Treatment
Currently there are no medications or surgical procedures
approved for the treatment of NAFLD. Several agents
have been tested, including vitamin E and the thiazolidine-
diones class of diabetes medications [21–24], though limi-
tations have been identified with both. In the PIVENS
(Pioglitazone, Vitamin E, or Placebo for NASH) trial, vita-
min E and pioglitazone both improved hepatic steatosis
and lobular inflammation but not fibrosis, and pioglita-
zone was associated with weight gain (4.8 % increase in
body weight) [22, 25]. Rosiglitazone improved steatosis
but not any other histologic lesions in patients with
NASH, and was also associated with weight gain [21].
Weight loss via lifestyle modification remains the
foundation for current clinical management of the dis-
ease [26, 27]. A reduction in weight of 3-5 % improves
biochemical markers and steatosis in NAFLD patients
while 10 % weight loss is required for improvement in
inflammation and NASH regression [28, 29]. Still, identi-
fication of effective and high impact lifestyle interven-
tions to achieve this degree of weight loss is critically
needed to provide evidence-informed recommendations.
Gut microbiota in NAFLD, obesity and associated
co-morbidities
Gut microbiota have emerged as an important environ-
mental factor influencing the pathogenesis of NAFLD
[9, 30]. Since the liver and intestine are connected ana-
tomically and via the hepatic portal system, the gut
microbiota and their metabolic by-products may influ-
ence hepatic pathology. The connection between the
gut microbiota and NAFLD is incompletely understood,
however, and a recent review only identified four ani-
mal and five human studies characterising microbial
profiles in NAFLD [31]. In mice fed a high fat diet,
Lactobacillus positively correlated with the severity of
hepatic steatosis and the effect was attributed to the
impact of Lactobacillus on bile acid metabolism [32].
Supplementing a high-fat diet with Bifidobacterium
pseudocatenulatum CECT 7765 over seven weeks in-
creased Bifidobacterium and decreased Enterobacteria-
ceae; changes associated with a reduction in hepatic
steatosis in conjunction with weight loss and improved
insulin sensitivity [33]. Finally, inflammasome-deficient
mice displayed a dysbiotic microbiome that exacerbated
hepatic steatosis and inflammation [34].
In humans, using experimental dietary choline deple-
tion (known to induce hepatic steatosis), higher baseline
levels of Gammaproteobacteria correlated with a lower
risk for fatty liver. Conversely, Erysipelotrichi correlated
with a higher risk, suggesting a person’s microbiome can
impact their susceptibility to fatty liver in response to
choline deficiency [35]. Quantification of gut microbiota
in NAFLD patients has produced conflicting results
[36–38] and differences within phyla highlight the need
for deeper sequencing. Furthermore, in many studies the
effects of NAFLD were not isolated from those of simple
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obesity. From a treatment perspective, administration of a
probiotic combination increased Bacteroidetes and de-
creased Firmicutes after six months, which correlated with
reduced hepatic fat [39]. Further, a meta-analysis evaluat-
ing probiotic treatment in NAFLD, found reduced liver
enzymes (ALT, AST), TNF-α, total cholesterol and insulin
resistance, suggesting that altering gut microbiota may
beneficially affect NAFLD [40].
Changes in the gut microbial environment in obesity
and type 2 diabetes have been well-documented. These
conditions, which are closely tied to NAFLD develop-
ment, are known to be associated with changes in the
vast and diverse communities of microorganisms that
live in the human intestinal tract [41–44]. Although not
unanimously shown, obesity is associated with a
phylum-wide increase in Firmicutes and a reduction in
Bacteroidetes [42, 45–47]. This shift is believed to en-
hance energy harvest, thereby promoting weight gain,
hyperglycemia and insulinemia [43, 48–50]. The micro-
biota also affect the integrity of the gut barrier; in the
case of obesity and high fat diets, changes in gut integ-
rity translate to increased intestinal permeability and
translocation of endotoxin (lipopolysaccharide from
Gram-negative bacteria) [9, 51–53]. Increased leakage
of endotoxin into the bloodstream is called metabolic
endotoxemia and has been linked to the onset of meta-
bolic diseases [52]. In NAFLD patients, endotoxin levels
are elevated [54, 55] and have been associated with small
intestinal bacterial overgrowth [9, 56, 57]. The microbiota
can also produce endogenous ethanol [9] and ~300 other
volatile organic compounds (VOC) [58], some of which
may contribute to liver injury. Recently, it has been
shown that obese NAFLD patients have an altered micro-
biome and unique fecal VOC profile compared to healthy
controls [38]. While the effect of VOC on liver function
is unknown, it is plausible that excess VOC may contri-
bute to a state of elevated inflammation and hepatocyte
stress. Given the profound metabolic impact of the gut
microbiota to the host, therapeutic manipulation of this
community may aid in treatment of NAFLD.
Prebiotics
Prebiotics are nondigestible food ingredients that are
fermented in the gut and modulate the microbiota in a
manner beneficial to the host [59–61]. Prebiotic fiber is
found naturally in common foods such as asparagus,
garlic, leeks and onions [62]. The average intake of pre-
biotic fiber is estimated to be 1-4 g/d in the Unites
States and 3-11 g/d in Europe [63].
There are numerous animal and human studies that
point to the potential of prebiotics to treat NAFLD
[60, 64–67]. Our lab and others have consistently
shown that prebiotic supplementation is associated with
lower body weight and/or reduced weight gain in normal
[68], genetically obese [69] and high fat, high sucrose-fed
[70, 71] rats. We were also the first to report that prebiotic
supplementation improves weight loss and reduces energy
intake in overweight and obese adults compared to pla-
cebo [72], which has since been shown in patients with
type 2 diabetes [73]. Increases in satiety hormones ob-
served with prebiotics, including glucagon-like peptide-1
(GLP-1) and peptide YY (PYY) and decreases in the orexi-
genic hormone ghrelin, likely mediate some of the re-
duced ad libitum energy intake contributing to weight
loss [68, 70–72, 74, 75]. These modifications observed
with prebiotic supplementation are notable because
greater satiety and lower hunger are associated with im-
proved adherence to weight loss interventions [76–79].
Further, the metabolic benefits of prebiotics were evalu-
ated in a recent systematic review of 26 randomized con-
trolled trials [80], where prebiotics were shown to
improve satiety, postprandial glucose and insulin in both
healthy and obese individuals.
Prebiotics alter gut microbiota in favor of host health
[63], including modifying gut barrier integrity and endo-
toxin translocation. For example, prebiotics increase
Bifidobacterium which is correlated with lower serum
endotoxin levels [81]. In addition, prebiotics stimulate
the gut trophic hormone glucagon-like peptide-2, which
can modulate endotoxin translocation via effects on epi-
thelial tight junctions [53]. Steatosis itself increases the
vulnerability of the liver to injury from endotoxin; while
other NAFLD treatment such as vitamin E and thiazoli-
dinediones may reduce steatosis, there is no human evi-
dence that currently suggests vitamin E or the glitazones
attenuate endotoxin levels.
The NAFLD Activity Score (NAS) is a histologically-
based tool used to grade steatosis, lobular inflammation
and ballooning in patients with NAFLD. While weight
loss has been shown to reduce NAS, this is largely
driven by reductions in steatosis but not ballooning or
inflammation, and it does not appear to affect fibrosis
[82]. By contrast, we have preliminary histopathological
evidence from a pilot trial suggesting that prebiotic fiber
improves several hepatic outcomes (i.e. fibrosis) that
would augment improvements from weight loss alone
(i.e. steatosis) (Unpublished observations; RA Reimer,
MR Bomhof ). This finding is supported by a recent re-
port that 24 weeks of prebiotic (fructooligosaccharide)
plus probiotic (Bifidobacterium longum) reduced serum
AST, endotoxin and hepatic steatosis in NASH patients
[83]. Our recent review [61] highlights convincing evi-
dence from animal and human studies for the potential
of prebiotics as a multi-target strategy to treat NAFLD.
It is our hypothesis that prebiotic supplementation, as
an adjunct to lifestyle-mediated weight loss, will improve
hepatic and metabolic pathways beyond those targeted
by weight loss alone.
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Specific objectives
The primary objective of this study is to determine
the efficacy of a prebiotic supplement in combination
with registered dietitian supported weight loss in re-
ducing hepatic injury and liver fat in NAFLD patients
over 6 months. Secondary objectives include deter-
mining the effect of prebiotic supplementation plus
weight loss on appetite, body composition, glucose
tolerance, inflammatory cytokines, and potential
mechanisms related to gut microbiota, volatile organic
compounds, and de novo lipogenesis. The research
study is novel in that it has been designed to provide
comprehensive information on liver health outcomes
in NAFLD patients in conjunction with a mechanistic
investigation into several of the “multi-hits” thought
to promote NAFLD and its progression to NASH.
Given the primary objective of determining the im-
pact of prebiotics on hepatic injury and liver fat in
NAFLD patients from baseline to 6 months, patients
will undergo a liver MRI, a FibroScan and blood
FibroTest. Changes in gut microbiota, VOCs, and LPS
will elucidate the effects of prebiotic modulation of the
gut microbiota and their metabolic by-products. The
impact of prebiotics on obesity-related outcomes will
be evaluated through anthropometrics, subjective ap-
petite ratings and satiety hormone responses. Insulin
resistance is also closely associated with NAFLD and
the effects of prebiotics on glucose regulation will be
assessed via responses to an oral glucose challenge. In-
flammatory cytokines are another potential “hit” and the
effect of prebiotics on plasma inflammatory markers
will be quantified. Finally, there is potential for prebi-
otics to reduce lipogenesis due to its effects on glucose
tolerance, food intake, and gut microbiota, and this will
be investigated via measurement of de novo lipogenesis.
This trial is designed to test whether prebiotic supple-
mentation augments the reduction in steatosis attrib-
uted to weight loss alone. We hypothesize that the
addition of a prebiotic supplement to a registered
dietitian-led weight loss intervention, will improve hep-
atic injury and steatosis to a greater extent than weight
loss alone.
Methods/design
Ethics, consent and permission
This proposal has been approved (REB14-2464) by the
Conjoint Health Research Ethics Board of the University
of Calgary (Calgary, AB, Canada). Voluntary, written, in-
formed consent will be obtained from each participant.
Design
The study is a single-center double blind, placebo con-
trolled, parallel group study. Patients will be random-
ized to a 16 g/d prebiotic supplemented group or
isocaloric placebo group for 24 weeks. All participants
will receive individualized dietary counseling sessions
with a registered dietitian to achieve 10 % weight loss.
Inclusion criteria
Adult participants (aged 18–65, BMI ≥25 kg/m2) diagnosed
with NAFLD on the basis of abnormal liver enzymes
(ALT > 1.5x upper limit of normal) and ultrasonography
[84] will be recruited from the South Health Campus Fatty
Liver Clinic and the surrounding community in Calgary,
Alberta, Canada. Individuals with type 2 diabetes treated
with diet and exercise alone or metformin will be included,
as well as individuals with aspartate aminotransferase and
alanine aminotransferase ≤10x upper limit of normal.
Exclusion criteria
Exclusion criteria include other causes of liver dis-
ease such as viral hepatitis and alcoholic liver dis-
ease; cirrhosis of the liver (FibroScan >17.5kPa or
FibroTest >0.8) or clinical features of cirrhosis; alco-
hol consumption >20 g/day (2 standard drinks) in
women or > 30 g/d (3 drinks) in men; alternate (e.g.
TPN) or concomitant etiology for abnormal liver en-
zymes; history of decompensated liver disease includ-
ing ascites, encephalopathy or variceal bleeding;
concomitant use of any weight loss medication or
herbal weight loss products, previous bariatric or
other intestinal surgery known to affect food intake
or digestive function; presence of active infection,
pregnancy or lactation; regular use of a probiotic or
prebiotic supplement within 3 months prior to enroll-
ment; antibiotic use within 3 months prior to enrollment;
weight loss >3 kg within the preceding 3 months to
enrollment; uncontrolled cardiovascular or respiratory
disease, active malignancy, or chronic infections; use
of agents such as vitamin E, omega-3 fatty acids or
medications with evidence for effects on NAFLD (pio-
glitazone, GLP-1 analogues, dipeptidyl peptidase IV
inhibitors, ursodeoxycholic acid); and patients with
type 2 diabetes where HbA1c is >9 %.
Randomization
Participants will be randomized in equal numbers to
two groups, stratified by sex, BMI, and age for alloca-
tion into prebiotic or placebo arms. Randomization se-
quences will be prepared by an independent statistician
and entered into a web-based central randomization
program. Sequences will not be revealed to investiga-
tors or study staff. Randomization will be in blocks of 4
within each sex/age/BMI stratum. To maintain blinding
of the trial coordinator and registered dietitian, a re-
search assistant with no involvement in the study will use
the central randomization program at the randomization
visit. Study personnel will be unaware of treatment
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allocation prior to the assignment of interventions, using
sequentially numbered, opaque, sealed envelopes to main-
tain allocation concealment. The clinical trial coordinator
will enroll participants. Participants, research staff and
outcome assessors will be blinded to participants’ assigned
group. Participants will receive the prebiotic or placebo
supplement in identical foil packets to maintain blinding.
An overview of the study design and measurement out-
comes is presented in Fig. 1.
Participants will be randomly assigned to a 16 g/day
prebiotic dose [Synergy1 (oligofructose-enriched inulin),
Beneo-Orafti, Belgium] or an equicaloric dose of pla-
cebo [maltodextrin] for 24 weeks. The dose will be
ramped up over two weeks and at full dose be con-
sumed as two 8 g packets/day (13.2 kcal/packet) or
two 3.3 g packets/day (13.2 kcal/packet) of maltodex-
trin. Participants will add the packet to 250 ml of
water and consume it 30 minutes prior to lunch and
dinner. The dose of 16 g/d was selected given previ-
ous work showing a reduction in serum AST in
NASH patients with prebiotic [85]. Compliance will
be assessed via packet counts.
Fig. 1 Schematic overviews of the a study design and b testing day protocols. *Blood work at Calgary Laboratory Services (CLS) includes:
glucose, lipids (total, LDL, HDL, TG), HbA1C, liver enzymes (ALT, AST, ALP), FibroTest (gamma-glutamyl transpeptidase, bilirubin, α2-macroglobulin,
haptoglobin, and apo-lipoprotein A1), CRP, and liver function biochemistries (creatinine, electrolytes, albumin, bilirubin). **Adipokines/Cytokines
include: adiponectin, MCP-1, TNF-α, IL-6 and IL-8. ***Satiety hormones include: active ghrelin, insulin, leptin, total GIP, active GLP-1, and total PYY
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Dietary weight loss intervention
All participants will be provided diet and lifestyle coun-
seling in one-on-one sessions with a registered dietitian.
Participants will be responsible for buying and preparing
their own food. The diet will be designed to achieve a
weight loss of 0.5-1.0 kg/week with an appropriate en-
ergy deficit based on anthropometrics and indirect calor-
imetry analysis. Participants will meet with the dietitian
for 10 in-person visits (1–2 h each). Nutrition education
and behavior modification strategies will be used to re-
duce intake of total energy, added sugars, sodium, and
processed food, and to maintain adequate protein intake.
Dietary intake during the phases will be assessed by
weighed 3-day food records. The dietitian will also con-
tact participants by phone each week to assess adher-
ence, address questions or issues that arise, and monitor
body weight. Body weight and waist and hip circumfer-
ences will be measured at each visit, and there will
be a fasting blood draw at the midpoint of the study
(week 12) to monitor blood chemistries (serum ami-
notransferases and lipids).
During the first phase (visits 1–4), participants will be
provided with two 7-day meal plans designed by the
dietitian. Meal plans will be personalized for each partic-
ipants, taking into consideration lifestyle and food pref-
erences based on questionnaires completed at screening.
Nutrition education components will include identifying
primary food sources of fat, carbohydrate, and protein,
reading nutrition labels, and sources of empty calories.
In the second phase (visits 5–8), the focus will be on be-
havior modification and achieving dietary autonomy.
This will be achieved through specific counseling which
will include planning and preparing meals in the home,
portion control, and choosing foods when dining out.
Counseling will also be tailored to each individual, based
on initial questionnaires related to food craving and be-
havior. During the final phase (visits 9 and 10), partici-
pants will be entirely responsible for planning their own
meals and counseling will focus on maintenance of diet-
ary behaviors.
Primary outcome
Hepatic injury and liver fat
The primary outcome is change in hepatic injury and
liver fat from baseline to 24 weeks. Improvement in
liver injury will be defined by reduction in non-
invasive and biochemical markers of fibrosis and in-
flammation. Fibrosis will be measured at baseline and
24 weeks using transient elastography (FibroScan), which
has a high sensitivity for diagnosis and prognostic stratifi-
cation of varying degrees of liver fibrosis [86, 87] and
the Fibrotest which is a composite of serological
markers and age and sex, that provides a quantitative
estimate of liver damage (age, sex, gamma-glutamyl
transpeptidase, bilirubin, α2-macroglobulin, haptoglo-
bin, and apo-lipoprotein A1) [88]. The newer XL
probe, specifically designed for obese patients, will be
used for FibroScan [86]. Magnetic resonance imaging
(MRI) will be performed at baseline and 24 weeks on
a 1.5 T scanner (GE Medical Systems, Milwaukee,
USA) to assess change in liver fat. MRI can detect fat
in microscopic quantities and with chemical shift im-
aging (CSI) has a sensitivity of 90 % and specificity of
91 % [89]. Although costly, MRI is a front-runner in
imaging modalities to quantify hepatic steatosis and
represents an acceptable alternative to invasive liver
biopsy. While still the gold standard in histological
assessment of NAFLD, biopsy is not without risk and
is limited by its lack of representation of the liver as
a whole [90].
Secondary outcomes
Anthropometrics and Dual Energy X-Ray Absorptiometry
Height will be measured at the beginning of the study
to confirm BMI. At each dietitian visit, body weight
will be measured using a calibrated balance beam
scale along with waist circumference and blood pres-
sure. Body composition will be assessed at baseline
and week 24 by DXA (Hologic QDR 4500, Hologic,
Inc., Bedford, MA).
Food record
Food and beverage intake will be assessed using 3-day
weighed food records at baseline, 4, 10, 16 and 24 weeks
using food scales and standardized forms provided to
the participants. Dietary adherence will be defined as
prescribed versus measured energy intake. Prior to the
start of the study all participants will attend a training
session delivered by the dietitian in which they will be
instructed on the use of the food scale and how to rec-
ord their food intake. Participants will then be instructed
to weigh and record all food consumed for 2 weekdays
and 1 weekend day. This information will be analyzed
with FoodWorks software (The Nutrition Company,
Long Valley, NJ). Food records will also be used to assess
dietary adherence.
Physical activity and sleep monitoring
Participants will be instructed to maintain their current
level of physical activity throughout the study. Physical
activity will be monitored at 0, 12, and 24 weeks using
a modified Godin’s Leisure Time Exercise Question-
naire that includes duration [91]. Objective monitoring
of sleep and physical activity will occur at baseline and
24 weeks. Participants will be provided with an Acti-
Graph wGT3X-BT (ActiGraph, Pensacola, FL) monitor
initialised at 30Hz to wear for five consecutive days.
Participants will be instructed to wear the monitor on
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their waist during waking hours (except when in con-
tact with water) and on their wrist while sleeping, as
the monitor has been validated in these positions [92].
At least 3 days of valid wear will be required for the
data to be included in the analysis [93]. ActiLife6
software (ActiGraph, Pensacola, FL) will be used to
convert data to 1-minute epochs. For physical activity,
counts per minute will be classified using predeter-
mined tri-axial vector magnitude cut-points for light,
moderate, hard or very hard 0–2690, 2691–6166,
6167–9642, and >9642 counts per min respectively
[94]. Sleep will be scored using the Cole Kripke algorithm
[95] included in the ActiLife software.
Subjective and objective assessments of appetite
Subjective ratings of appetite will be recorded by partic-
ipants at home following a meal, at the same time on
the same day, each week using a validated 100 mm VAS
[96, 97]. The questions asked based on how the partici-
pant felt over the past week are:
1) “How hungry do you feel?” anchored by “I am not
hungry at all” and “I have never been more hungry”.
2) “How satisfied do you feel?” anchored by “I am
completely empty” and “I cannot eat another bite”.
3) “How strong is your desire to eat” anchored by “I
have no desire to eat” and “I have a great desire to
eat”.
4) “How full do you feel?” anchored by “Not at all full”
and “Totally full”.
5) “How much do you think you could eat?” anchored
by “Nothing at all” and “A lot”.
6) Over the course of the past week, my appetite was:
“Much lower than usual” and “Much higher than
usual”.
Quality of life and gastrointestinal feelings
Quality of life will be measured at baseline and
24 weeks with the SF-36v2 Health Survey question-
naire [98]. This is a 36 question self-administered
questionnaire used to measure functional health and
well-being. Bowel habits and gastrointestinal feelings
will be assessed at baseline, 12 and 24 weeks using
our standard gastrointestinal feelings ratings form
(abdominal comfort, bloating, flatulence, rumbling of
stomach) and bowel habits questionnaire (number of
bowel movements and Bristol Stool Chart).
Oral glucose tolerance test (OGTT)
Participants will consume a standardized menu the day
prior to the OGTT to ensure consistency in macronutri-
ent consumption prior to testing. The menu has been
designed by a dietitian and includes 3 meals and 2
snacks. Participants will be instructed to finish dinner
and then to not eat after 8 pm. The following morning,
a baseline blood sample will be taken via a cannula
inserted into the antecubital vein. Subsequently, partici-
pants will consume a 75 g oral glucose drink and blood
samples will be drawn at 30, 60, 120 and 180 minutes.
The OGTT will be conducted at baseline and follow-up
(24 weeks). Blood will be centrifuged and plasma frozen
at −80 °C for future analyses. Glucose will be quantified
using a glucose trinder assay (Stan Bio, Boerne, TX,
USA) as per our previous work [72].
Plasma lipids, liver biochemistry, and inflammatory
markers
At baseline, 12 and 24 weeks, a fasting blood sample will
be taken for measurement of plasma HbA1c, lipids, CRP,
liver enzymes (ALT, ALP, AST), FibroTest, and bio-
chemical markers of liver function (creatinine, electro-
lytes, albumin, bilirubin). Blood will be drawn at and
analysed by Calgary Laboratory Services (Calgary, AB,
Canada). Serum adipokines and inflammatory markers
(adiponectin, MCP-1, TNF-α, IL-6 and IL-8) will be
quantified using Milliplex kits (Millipore, Billerica, MA)
from fasting samples obtained at baseline and follow-up
(24 weeks) testing.
Satiety hormones
At each of the five time points during the OGTT,
additional blood samples will be collected for meas-
urement of satiety hormones including insulin. Blood
will be drawn into a cooled EDTA vacutainer tube con-
taining diprotinin-A (0.034 mg/ml blood; MP Biomedicals,
Irvine, CA); Sigma protease inhibitor (1 mg/ml blood;
Sigma Aldrich, Oakville, ON, Canada) and Roche Pefabloc
(1 mg/ml of blood; Roche, Mississauga, ON, Canada)
[72]. Blood will be centrifuged within 30 min and
plasma analyzed for ghrelin (active), insulin, leptin,
glucose-dependent insulinotropic polypeptide (GIP)
(total), GLP-1 (active), and PYY (total) concentrations
using a Milliplex MAP Human Gut Hormone Panel
Kit (Millipore, St Charles, MO). Surrogate markers of
insulin resistance, HOMA and QUICKI, will be quan-
tified as per our previous work [99].
Mechanistic secondary outcomes
Gut Microbiota
Stool will be collected at baseline and follow-up for ana-
lysis of gut microbiota. Participants will be instructed on
proper methods for stool collection and all materials will
be provided in a convenient specimen collection kit.
Each subject will collect 2 tablespoons of stool into a
pre-labeled sterile container. The container will be
sealed, placed in a biohazard bag, and immediately
stored in a standard home freezer (−20 °C). The speci-
men will be transported to our research lab within 4 days
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of collection in a Styrofoam container on an ice pack
and transferred to −80 °C for longer term storage. For
analysis of fecal microbiota, total DNA will be extracted
from 150 mg of stool using the Qiagen QIAamp™ DNA
Stool Mini Kit. Uniform bacterial DNA extraction is en-
sured by the addition of a 2-minute mechanical bead
(0.1 mm zirconia:silica) beating step following addition
of buffer ASL to the samples. DNA quantity and purity
will be measured using a nanoscale spectrophotometer.
To understand the functional and metabolic capabilities
of the gut microbiota [100] and how prebiotics impact
the metabolic capacity of the entire microbiome, whole
genome shot-gun sequencing will be performed to
analyze both the microbial composition and potential
metabolic functions at the University of Alberta’s Ap-
plied Genomic Center. Fecal DNA will be used as input
for the Illumina Nextera® XT DNA Sample Preparation
Kit to construct indexed paired-end DNA libraries as
previously described [101]. A final constructed paired-
end indexed library set will be run on a Bioanalyzer
2100 using Agilent High Sensitivity DNA Kit to acquire
library average size distribution (Agilent Technologies,
Santa Clara). Final libraries will be quantified using a
Qubit® 1.0 fluorometer and the Qubit® dsDNA HS assay
(Life Technologies, Carlsbad). Obtained quantification
and average size distribution of the final Nextera® XT
libraries will be used to calculate molarity of the library
according to the Nextera® Library Validation and Cluster
Density Optimization Technical Note. Libraries are nor-
malized to 2nM and pooled together using equal volume
aliquots. The pooled and indexed library set is dena-
tured, diluted, and sequenced on an Illumina MiSeq. Se-
quencing parameters consist of: paired-end 251 bp dual
index sequencing chemistry using MiSeq Reagent Kit-v2
(500 cycle) and FASTQ Only workflow. Produced
FASTQ files are then subjected to bioinformatics ana-
lysis. The raw FASTQ files are first filtered for adapter
sequences and end trimmed of bases with quality less
than 15. Read ends are then aligned against a set of
mitochondrial databases with SOAPalign, with unaligned
reads passed to each successive alignment. Read ends
unaligned to mitochondrial databases are aligned to
human, bacterial, and viral databases generated from
NT, using SOAPalign. SpecI (http://vm-lux.embl.de/
~kultima/MOCAT/) will be used to determine species
composition and HUMAnN (http://huttenhower.sph.-
harvard.edu/humann) used for the characterization of
microbial pathways in the communities.
Endotoxin
Serum endotoxin will be measured using a PyroGene re-
combinant factor C endotoxin detection kit (Lonza,
Walkersville, MD) as per our previous work [75].
Volatile organic compounds
Functional capabilities of microbiota will be assessed
in terms of bacterial production of VOC. At the time
of analysis, fecal samples will be thawed and a car-
boxen/polydimethyl-siloxane solid phase micro-extraction
(SPME) fiber will be placed into the sample collection vial
by injecting it through the septum in the cap. The SPME
fiber will be left in the vial headspace for 20 minutes to
fully absorb the VOC. The fiber will then be retracted into
the needle and transferred to the injector port for gas
chromatographic (GC) analysis. Two GC machines con-
nected in serial are used to resolve VOC that are detected
by mass spectrometry (MS). Compounds are then identi-
fied by reference to the NIST 08 MS library.
De Novo lipogenesis
Energy reduction and weight loss significantly reduces
lipogenesis, contributing to reduction in steatosis
[102–106]. As part of our mechanistic investigation,
fatty acid synthesis will be measured from fasting
plasma samples using the deuterium incorporation
method as per established methods [12, 107]. This
protocol will be performed at a baseline visit prior to
the OGTT (Fig. 1). Briefly, deuterium-labeled water
(2H2O; 99.9 atom %; Cambridge Isotope Laboratories,
Inc.; Tewksbury, MA) will be provided to participants
at a dose of 1 g/kg body water (estimated as 60 % of
body weight) to ingest [107]. On day 1, a fasting
blood sample will be taken to measure background
2H enrichment, and on day 6, participants will ingest
a single dose of 2H2O, as well as be provided with a
second dose diluted in 1.5 L of water to consume at
regular intervals over the next 24 h [107]. On day 7
at the inpatient visit, a fasting blood sample will be
taken for measurement of 2H incorporation into tri-
glyceride (TG) and plasma water. Plasma will be
ultracentrifugated to isolate total TG-rich lipoproteins,
which at fasting will be primarily VLDL arising from
the liver [12, 108]. Samples will be stored at −80 °C
until further analysis. Folch extraction and thin layer
chromatography will be used to isolate the TG por-
tion, which will be saponified and methylated to pre-
pare fatty acid methyl esters (FAME) for GC/P/IRMS
analysis [107]. Samples will be analyzed for 2H en-
richment in major lipogenic fatty acids (14:0, 16:0,
16:1, 18:0, and 18:1). Proportion of newly-synthesized
fatty acid will be calculated for each fatty acid using
established equations [107].
Sample size calculation
Our sample size is based on the primary outcomes of
hepatic injury and liver fat. For hepatic injury, we used
pilot data from our lab to determine that a sample size
of n = 19 in each group would have 80 % power to detect
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a difference in liver stiffness of 4.1 kPa with FibroScan
assuming a standard deviation of 4.0 kPa and a 0.025
two-sided significance level. For the Fibrotest [109], a
sample size of n = 10 per group would have 80 % power
to detect a difference in Fibrotest score (0.0 to 1.0) of
0.08 assuming a standard deviation of 0.056 and a 0.025
two-sided significance level. For liver fat measured by
MRI [110], a sample size of n = 25 per group will have
80 % power to detect a difference in hepatic fat of 4.4 %
assuming a standard deviation of 5.0 % and a 0.025 two-
sided significance level. Based on these calculations, we
will enroll n = 25 per group. Assuming a dropout rate
similar to that in our previous prebiotic trial [72] of ap-
proximately 20 %, we will recruit a total of 60 partici-
pants (n = 30 per group).
Statistical analyses
Statistical analyses will be performed using SPSS 22.0
software (IBM, Armonk, NY). Values with skewed dis-
tribution will be logarithmically transformed prior to
analysis. Baseline characteristics will be compared be-
tween groups using chi-square for categorical variables
and t-tests for continuous variables. Primary analysis
will be performed on an intent-to-treat basis, regardless
of subject compliance. The primary outcome measures
are change from baseline to 24 weeks in hepatic injury
(Fibrotest, FibroScan) and liver fat (percent measured
by MRI). ANCOVA, with testing for confounding fac-
tors (sex) and potential covariates (BMI, age and fasting
insulin) will be used to assess the difference between
groups at weeks 0 and 24. Should the main effect of
diet be significant, Tukey’s multiple comparison test
will be used. Secondary outcomes measured at 0 to
24 weeks (e.g. satiety hormones, body fat, glycemia and
insulinemia) will be analyzed with ANCOVA as above.
For variables measured over time (e.g. body weight, sa-
tiety hormones and glucose at 0, 30, 60, 120 and 180 mi-
nutes), a mixed model of repeated measures ANCOVA
will be applied to examine the effect of treatment, time
and their interaction. Our planned secondary analysis
will be per protocol with all participants who complete
the 24 week intervention and are compliant based on
consumption of ≥80 % the product doses. Cases with
missing outcome data will be excluded from analysis.
Results will be considered statistically significant (2-
sided) at P ≤ 0.025 (Bonferroni adjustment for 2 pri-
mary outcomes).
Shotgun sequencing and GC-MS produce large data-
sets profiling microbiota composition and function and
VOC metabolites, respectively. Binary as well as abun-
dance data will be used in modeling VOC data. OPL-S
coefficients determine the major variables contributing
to discrimination in the model. VOC of interest will be
identified with 90 % probability by referencing to mass
spectral library standards of the National Institute of
Standards and Technology (NIST08) database. Bacterial
communities will be quantitatively assessed by Bray-
Curtis dissimilarity matrix and Shannon-Wiener diver-
sity index. Relative abundance data will be transformed
[log(X + 1)] prior to generation of the resemblance
matrix. To reduce dimension of explanatory variables
and identify bacteria that were potentially acting in
groups we will conduct hierarchical clustering analysis
using Spearman rank correlation with complete linkage
and groups identified based on correlations >0.5. Dis-
tinct bacteria tax identified from hierarchical clustering
analysis will be compared across groups and time-
points using formal parametric/non-parametric statis-
tical methods such as the Dirichlet-multinomial distri-
bution test, Mantel test, NP-Manova etc. We will
analyze the prebiotic and placebo participants in terms
of fecal microbiota, VOC, lipogenesis, clinical data, and
host metabolic, nutritional, and inflammatory parame-
ters using differential correlation analysis. Features will
be compared using a Spearman’s rank order correlation
coefficient and correlations above a defined threshold
will be compared between groups. We will then graph
the correlations that are statistically different between
the groups to identify the pairs of features (i.e. the
different VOC metabolites and bacteria between treat-
ments) that distinguish the responses. The network
models will be visualized in the popular open-source
Cytoscape software.
Discussion
The prevalence of NAFLD continues to increase world-
wide in parallel with obesity and insulin resistance.
Despite a multiplicity of factors working in concert to
promote the development and progression of the dis-
ease, there is sufficient evidence linking NAFLD with
dysbiosis of the gut microbiota to warrant an interven-
tion aimed at prebiotic-mediated manipulation of the
gut microbiota. Further support for the immediate need
for this trial comes from the realization that there are
few approved treatment options for NAFLD patients.
While the standard of care for patients with NAFLD fo-
cuses on weight loss through diet and exercise, the dif-
ficulty in achieving and maintaining weight loss is well
documented. Given that dietary prebiotic intake is asso-
ciated with subjective improvements in satiety, there is
the added potential for prebiotics to improve adherence
to the weight loss intervention. Although approved
therapies for NAFLD are still lacking, capitalizing on
the gut microbiota–liver axis may provide new thera-
peutic targets in future.
The planned double blind, randomized clinical trial
will determine whether adding prebiotic to a 6-month
weight loss intervention will augment improvements in
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hepatic steatosis and fibrosis attributed to weight loss
alone in the placebo group receiving an identical weight
loss intervention but without supplementation. The ex-
ploration into the mechanisms of action is critically im-
portant in advancing treatment options for NAFLD and
this study will specifically address de novo lipogenesis
and metagenomic analysis of gut microbiota and their
associated metabolic by-products (i.e. VOCs). Ultimately
this clinical trial will advance our understanding of
the magnitude to which NAFLD can be treated with
a dietary intervention aimed at modulating the gut
microbiota.
The proposed study design using daily packets to
be consumed with water prior to a meal is feasible as
indicated by our previous research [72] and is similar
to soluble fiber supplements already on the market.
More promising, however, is the versatility of pre-
biotics. Foods supplemented with prebiotics are
already in production because the physical properties
and sweet taste allows manufactures to decrease the
caloric value while maintaining the palatability and
texture of the food [111]. This ease of incorporation
is important given the surge in interest in manipula-
tion of the gut microbiota to prevent or treat condi-
tions such as obesity and inflammatory bowel disease.
While other options including fecal transplantation
and antimicrobial-based interventions are being tested
as viable means to manipulate the gut microbiota,
targeted dietary interventions such as prebiotics or
probiotics are easy to administer and for the most
part have good safety and tolerance records [112].
While both prebiotics and probiotics are promising
means to manipulate the gut microbiota, unlike prebi-
otics, probiotics must remain viable during storage
and also be capable of surviving the harsh intestinal
environment of the host in order to exert their bene-
ficial effects [113]. Additionally, given the well-
established health promoting properties of prebiotics
and their tolerability, they could be used not only as
a treatment but also as a prophylactic.
This trial will assess the ability of a prebiotic to im-
prove overall health in a group at high-risk for a host
of metabolic diseases. Improvement in liver health is
expected, as are improvements in other predictors of
the metabolic syndrome. Ultimately, the research will
provide clinical evidence for a potential low-risk treat-
ment option for NAFLD patients. Should the pre-
biotic intervention prove beneficial, it could have a
significant impact on the ability of health professionals to
recommend evidence-based targeted dietary interventions
for managing NAFLD.
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